VALIANT (Valsartan Heart Failure Trial)

VALIANT (Valsartan Heart Failure Trial)
Name	VALIANT (Valsartan Heart Failure Trial)
Acronym	VALIANT
Phase	Phase III
Condition	Heart failure; Myocardial infarction
Intervention	Valsartan; Captopril; Valsartan plus Captopril
Sponsor	Bristol-Myers Squibb; Novartis
Start date	1998
Completion date	2001
Participants	14,703
Primary outcome	All-cause mortality

VALIANT (Valsartan Heart Failure Trial) was a large, randomized, controlled, multicenter clinical trial evaluating the angiotensin II receptor blocker valsartan compared with the angiotensin-converting enzyme inhibitor captopril and their combination in patients with heart failure or left ventricular dysfunction after myocardial infarction. The trial enrolled patients across multiple countries and was intended to clarify outcomes associated with renin–angiotensin system blockade following acute myocardial infarction. VALIANT informed guideline recommendations and regulatory discussions concerning post-myocardial infarction management and pharmacotherapy for heart failure.

Background

The trial arose amid evolving evidence from trials such as CONSENSUS, SOLVD, and SAVE regarding blockade of the renin–angiotensin system in myocardial infarction and congestive heart failure. Concerns about residual mortality after acute myocardial infarction despite reperfusion strategies like percutaneous coronary intervention and thrombolysis prompted comparative effectiveness research involving angiotensin II receptor blockers exemplified by losartan and valsartan. Regulatory interest from agencies such as the Food and Drug Administration and commercial development by firms including Novartis and Bristol-Myers Squibb also shaped trial design. Investigators sought to determine whether valsartan matched or exceeded outcomes seen with established therapy captopril, formerly studied in trials sponsored by institutions like the National Heart, Lung, and Blood Institute.

Study Design and Methods

VALIANT was a multicenter, randomized, double-blind, active-controlled, noninferiority and safety trial coordinated by academic consortia and contract research organizations with endpoints adjudicated by blinded committees. The protocol specified comparison arms for valsartan monotherapy, captopril monotherapy, and combination therapy with hierarchical statistical testing and prespecified subgroup analyses. Primary outcome assessment employed time-to-event analysis with hazard ratio estimation using Cox proportional hazards model methodology overseen by independent data monitoring committees convened under charter agreements similar to those used in trials like HOPE. Enrollment, randomization, and interim analyses followed Good Clinical Practice standards endorsed by organizations such as the World Health Organization and International Council for Harmonisation.

Participants and Baseline Characteristics

The trial enrolled approximately 14,703 patients who recently experienced an acute myocardial infarction with evidence of left ventricular systolic dysfunction or clinical heart failure. Sites spanned North America, Europe, Latin America, and Asia, reflecting networks linked to institutions such as Mayo Clinic, Cleveland Clinic, and major university hospitals. Baseline characteristics included mean age, sex distribution, prevalence of diabetes mellitus, prior coronary artery bypass grafting, hypertension, and prior myocardial infarction, comparable to populations in trials like GISSI and VALIANT-era registries. Enrollment criteria mirrored inclusion/exclusion patterns used in prior post-MI heart failure trials and allowed concomitant evidence-based therapies including beta-blockers and diuretics, similar to regimens studied in MERIT-HF and COPERNICUS.

Interventions and Comparators

Participants were randomized to receive valsartan monotherapy, captopril monotherapy, or the combination of valsartan plus captopril with dose-titration protocols and blinding procedures. Captopril dosing followed schedules validated in earlier trials such as AIRE while valsartan dosing reflected pharmacologic development data from studies led by developers including Novartis. Background care permitted therapies recommended by contemporary guidelines from bodies like the European Society of Cardiology and the American College of Cardiology including antiplatelet agents, statins such as simvastatin, and reperfusion strategies performed in centers performing coronary artery bypass surgery or percutaneous coronary intervention.

Outcomes and Results

The primary endpoint was all-cause mortality, with secondary endpoints including cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, and composite cardiovascular outcomes. VALIANT demonstrated that valsartan was noninferior to captopril for all-cause mortality and provided similar reductions in cardiovascular mortality and heart-failure hospitalization compared with captopril, with hazard ratios and confidence intervals reported in the main publication. Combination therapy did not confer additional survival benefit and was associated with different safety signals compared with monotherapy, mirroring findings from combination-therapy analyses in other trials such as ONTARGET. Subgroup analyses examined effects across strata including age, sex, diabetes status, and reperfusion modality, analogous to analyses commonly reported in trials like CHARM and PEACE.

Safety and Adverse Events

Adverse event monitoring captured hypotension, renal dysfunction, hyperkalemia, cough, and angioedema. Cough was more commonly associated with captopril, consistent with mechanisms involving bradykinin, whereas valsartan exhibited a lower incidence of that adverse event. Combination therapy increased rates of renal impairment and symptomatic hypotension relative to monotherapy, outcomes that influenced regulatory labelling discussions and safety advisories similar to those following trials like RALES and ONTARGET. Independent safety committees and pharmacovigilance teams reviewed serious adverse events and protocol deviations throughout the trial.

Interpretation and Impact on Clinical Practice

VALIANT contributed evidence that angiotensin II receptor blockade with valsartan provides mortality outcomes comparable to ACE inhibition with captopril after myocardial infarction complicated by left ventricular dysfunction or heart failure, and that routine combination therapy offers no incremental survival advantage while increasing adverse events. The results informed guideline updates from the American College of Cardiology and the European Society of Cardiology, influenced prescribing patterns in hospitals such as Massachusetts General Hospital and Johns Hopkins Hospital, and guided subsequent comparative-effectiveness research and regulatory policy. Subsequent trials and meta-analyses integrated VALIANT data when evaluating therapeutic strategies for post-infarction heart failure management and shaped clinical pathways in cardiology services worldwide.

Category:Clinical trials Category:Cardiology Category:Heart failure